Erratum: Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells (Hepatology (2007) DOI: 10.1002/hep.21872);Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells

Hepatology

Volumn 46, Issue 3, 2007, Pages 706-715

  Chen, Yongyan ^a   Wei, Haiming ^a   Sun, Rui ^a   Dong, Zhongjun ^a   Zhang, Jian ^b   Tian, Zhigang ^a,b,c  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON TETRACHLORIDE; CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 4; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN MULT1; PROTEIN RAE1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE SEVERITY; HEPATITIS B VIRUS; LIVER INJURY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

EID: 34548801289     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21946     Document Type: Erratum

References (35)

1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
2. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000;64:51-58.
3. Zheng BJ, Ng MH, He LF, Yao X, Chan KW, Yuen KY, et al. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinanr DNA composite in HBsAg transgenic mice. Vaccine 2001;19:4219-4225.
4. Trobonjaca Z, Kroger A, Stober D, Leithauser F, Moller P, Hauser H, et al. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol 2002;168:3763-3770.
5. Gilles PN, Guerrette DL, Ulevitch RJ, Schreiber RD, Chisari FV. HBsAg rerention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. HEPATOLOGY 1992;16:655-663.
6. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-Galactosylceramide in mice. J Immunol 2001;166:6578-6584.
7. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-790.
8. Cerwenka A, Lanier LL. Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev 2001;181:158-169.
9. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A 2003;100:9452-9457.
10. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al. Coordinated induction by IL-15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004;21:357-366.
11. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004;20:757-767.
12. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, et al. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 2003;18:41-51.
13. Sun R, Tian Z, Kulkarni S, Gao B. IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J Immunol 2004;172:5648-5655.
14. Takeda K, Hayakawa Y, Van Kaer L, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 2000;97:5498-5503.
15. Jaruga B, Hong F, Sun R, Radaeva S, Gao B. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol 2003;171:3233-3244.
16. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 1992;90:196-203.
17. Toyabe S, Seki S, Iiai T, Takeda K, Shirai K, Watanabe H, et al. Requiremenr of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997;159:1537-1542.
18. Ajuebor MN, Aspinall Al, Zhou F, Le T, Yang Y, Urbanski SJ, et al. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J Immunol 2005;174:8027-8037.
19. Miyagi T, Takehara T, Tatsumi T, Suzuki T, Jinushi M, Kanazawa Y, et al. Concanavalin a injection activates intraheparic innare immune cells to provoke an antitumor effect in murine liver. HEPATOLOGY 2004;40:1190-1196.
20. Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo F, et al. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000;191:105-114.
21. Honda A, Arai Y, Hirota N, Sato T, Ikegaki J, Koizumi T, et al. Hepatitis C virus sttuctural proteins induce liver cell injury in transgenic mice. J Med Virol 1999;59:281-289.
22. Chisari FV, Filippi P, Buras J, McLachlan A, Popper H, Pinkert CA, et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci U S A 1987;84:6909-6913.
23. Osman Y, Kawamura T, Naito T, Takeda K, Van Kaer L, Okumura K, et al. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide. Eur J Immunol 2000;30:1919-1928.
24. Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004;21:367-377.
25. Dandekar AA, O'Malley K, Perlman S. Important roles for gamma interferon and NKG2D in gammadelta T-cell-induced demyelination in T-cell receptor beta-deficient mice infected with a coronavirus. J Virol 2005;79:9388-9396.
26. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, et al. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 2003;197:1245-1253.
27. Campbell AE, Slater JS. Down-regulation of major histocompatibility complex class I synthesis by murine cytomegalovirus early gene expression. J Virol 1994;68:1805-1811.
28. Chen Y, Cheng M, Tian Z. Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell Mol Immunol. 2006;3:373-378.
29. Muhlen KA, Schumann J, Wittke F, Stenger S, Van Rooijen N, Van Kaer L, et al. NK cells, but not NKT cells, are involved in Pseudomonas aeruginosa exotoxin A-induced hepatotoxicity in mice. J Immunol 2004;172:3034-3041.
30. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274.
31. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-relared apoptosis-inducing ligand-dependent manners. Gastroenterology 2006;130:435-452.
32. Eberl G., MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000;30:985-992.
33. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, et al. Cutting Edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999;163:4647-4650.
34. Hayakawa Y, Takeda K, Yagita H, Kakuta S, Iwakura Y, Van Kaer L, et al. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur J Immunol 2001;31:1720-1727.
35. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005;201:1973-1985.